Infosys Ltd Share Price
(INFY)
₹1422.8
as on 04:01PM, 22 Apr 2025
🔔 Layoff Alert
Infosys terminates 240 entry-level employees, offering one month's salary and support for external training via NIIT and UpGrad.
Infosys Performance
Day's Low
Day's High
₹1,419.3Day's Price Range₹1,44052 Week's Low
52 Week's High
₹1,30752-Week Price Range₹2,006.45
| Returns % | |
| 1 Month Return | -8.9 % |
| 3 Month Return | -21.84 % |
| 1 Year Return | + 1.27 % |
| Market Stats | |
| Previous Close | ₹1,451.00 |
| Open | ₹1,440.00 |
| Volume | 94.00L |
| Upper Circuit | ₹1,596.10 |
| Lower Circuit | ₹1,305.90 |
| Market Cap | ₹6,02,638.53Cr |
Infosys Fundamentals
P/E Ratio
22.5
PEG Ratio
20.27
Market Cap
₹6,02,638.53 Cr
P/B Ratio
7.66
EPS
63.37
Dividend Yield
3.07
Sector
IT - Software
ROE
36.58
Mutual Fund Holdings of Infosys
Infosys Analyst Rating
based on 42 analysts
66.67%
Buy
28.57%
Hold
4.76%
Sell
Based on 42 analysts offering long term price targets for Infosys. An average target of ₹1762.81
Source: S&P Global Market Intelligence
Infosys Share analysis
Infosys price forecast by 42 analysts
Upside of21.49%
High
₹2270
Target
₹1762.81
Low
₹1350
Infosys target price ₹1762.81, a slight upside of 21.49% compared to current price of ₹1422.8. According to 42 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Infosys revenue growth forecast
Expected growth rate Q1, FY2027:20.50%
Forecast
Actual
Including amortisation and stock based compensations
Infosys EPS growth forecast
EPS estimate Q1, FY2027:19.11%
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - 22 Apr
02:47 AM
-Infosys launches a global capability center practice, appointing Deval Shah as leader to enhance GCC capabilities.
05:30 AM
-Infosys reports Q4 revenue growth of 4.8% in constant currency, with FY26 growth guidance of 0-3%.
08:30 AM
-HSBC maintains a buy rating on Infosys, setting a target price of Rs 1,700 despite recent revenue misses.
Today's Timeline - 22 Apr
09:30 AM
-Infosys shares fall 1.83%, continuing a downward trend with a 10.59% decline over the past month.
09:31 AM
-ICICI Securities lowers Infosys target price to Rs 1,470, maintaining a Hold rating amid weak growth outlook.
03:23 PM
-Infosys offers support measures for 240 terminated entry-level employees, including training and one month's salary.
Today's Timeline - 22 Apr
05:05 PM
-Infosys confirms layoffs of 240 entry-level employees due to assessment failures, providing various support measures.
Key events for Infosys Ltd
Infosys Faces Layoffs Amid Growth Challenges and Support Initiatives - 22 Apr, 2025
Infosys has announced layoffs of 240 entry-level employees while launching a global capability center practice. The company reported modest Q4 growth and received mixed analyst ratings, reflecting ongoing challenges in the IT sector.Infosys Reports Q4 Decline, Shares Rally on Guidance - 21 Apr, 2025
Infosys reported a 12% decline in Q4 net profit but saw a 3% share price increase due to management's guidance for FY26. Analysts have mixed views, with some maintaining bullish stances while others cut target prices amid ongoing demand challenges.Infosys Faces Decline Amidst Dividend and Growth Concerns - 20 Apr, 2025
Infosys reported an 11.7% decline in Q4 net profit and projected low revenue growth for FY26. The company announced a final dividend of ₹22 per share and secured $2.6 billion in large deals. Motilal Oswal set a target price of Rs 1650 for the stock.Infosys Announces Dividend Amid Layoffs and Earnings - 19 Apr, 2025
Infosys declared its highest-ever final dividend of Rs 22 per share for FY25, while also facing criticism for recent layoffs of trainees. The Q4 earnings season commenced with Infosys among the key players. LIC benefits significantly from the dividend payout, indicating strong financial performance despite workforce reductions.Infosys Faces Challenges Amid Weak Q4 Earnings - 18 Apr, 2025
Infosys reported a significant decline in Q4FY25 net profit and projected weak revenue growth for FY26. The company also announced layoffs and a substantial dividend, while brokerages adjusted target prices downward due to disappointing earnings.Infosys Faces Revenue Decline Ahead of Q4 Results - 16 Apr, 2025
Infosys is expected to report a decline in revenue and margins in its upcoming Q4 results. The company also announced a partnership with Spark New Zealand and leased significant office space in Pune, indicating ongoing operational expansion despite market challenges.Infosys Faces Challenges Amid CMO Recognition - 15 Apr, 2025
Infosys CMO Sumit Virmani was named in Forbes' entrepreneurial CMOs list. However, the company anticipates muted Q4 results with profit declines due to market challenges. Shares rose 1.16% ahead of earnings announcement.Infosys Faces Mixed Outlook Ahead of Q4 Earnings - 14 Apr, 2025
Infosys is set to announce its Q4 FY25 results amid mixed expectations due to global uncertainties. The company has revised its revenue growth guidance and received an upgrade from Susquehanna. Additionally, CMO Sumit Virmani was recognized in Forbes' top CMOs list.Infosys Set for Strong Q4 Earnings Announcement - 13 Apr, 2025
Infosys is scheduled to announce its Q4 results on April 17, 2025, with expectations of a 14.7% YoY profit increase and 11.2% YoY growth in net sales. The company will also hold investor calls to discuss results and outlook.Infosys Expands Collaborations Amid Stakeholder Changes - 10 Apr, 2025
Infosys has made significant moves, including acquiring Simplus, extending its partnership with AIB, and facing revenue growth challenges as LIC becomes its largest shareholder.Infosys Extends AIB Partnership Amid Target Price Cut - 09 Apr, 2025
Infosys announced an extended partnership with AIB for digital transformation while Jefferies cut its target price to ₹1,700. Shares fell 1.76% amid market concerns over IT demand.Infosys Stock Sees Gains Ahead of Earnings - 08 Apr, 2025
On April 8, 2025, Infosys shares increased by 3.02% in early trading, reflecting positive sentiment as the tech sector prepares for earnings announcements. However, the overall market sentiment remains volatile.Infosys Faces Revenue Decline Amid Market Challenges - 07 Apr, 2025
Infosys shares dropped 10% amid concerns over weak Q4 revenue growth and EBIT margin contraction due to wage hikes. Analysts recommend a SELL rating, predicting further challenges ahead.Infosys Board Meeting Scheduled for Q4 Results - 06 Apr, 2025
Infosys has announced a board meeting on April 17, 2025, to discuss and approve its audited financial results for Q4 and the fiscal year ending March 31, 2025, along with a potential final dividend.Infosys Stock Shows Mixed Signals in Market - 05 Apr, 2025
Infosys exhibits moderate momentum and is fairly valued, with strong financial health and low volatility. However, the sentiment score indicates a bearish outlook.Infosys Faces Revenue Decline Amid Market Concerns - 04 Apr, 2025
Infosys shares dropped 1.8% as the company anticipates a revenue decline for the March 2025 quarter, with forecasts of modest growth for FY26 amid economic uncertainty.Infosys Faces Legal Challenges and Stock Decline - 03 Apr, 2025
Infosys experienced a significant stock decline due to investor concerns over a legal battle with Cognizant and external pressures from US tariffs affecting the IT sector.Infosys Launches AI Stats Center Amid Revenue Concerns - 02 Apr, 2025
Infosys has launched an AI-powered Stats Center in partnership with Formula E to enhance fan engagement. However, Q4 revenue growth may be affected by seasonality and ramp-downs.Infosys Initiatives Amid Stock Decline and Collaborations - 31 Mar, 2025
Infosys is launching an incubator for employee ideas, preparing for Q4 results, facing a stock decline, and collaborating on Responsible AI with Linux Foundation Networking.Infosys Faces Market Challenges Amid Strategic Moves - 28 Mar, 2025
Infosys is navigating significant market challenges, with a steep share decline and lowered revenue expectations. However, it continues to pursue strategic partnerships and potential tax benefits.
Insights on Infosys Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 4 quarters, 6.36K Cr → 7.03K Cr (in ₹), with an average increase of 3.3% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 30.10% to 30.12% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.82% to 18.14% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, HCL Technologies Ltd has given 34.5% return, outperforming this stock by 43.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 13.05% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Wipro Ltd has given 3.2% return, outperforming this stock by 2.0%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 12.57% to 12.32% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, INFY stock has moved down by -8.9%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 42.62K Cr → 42.11K Cr (in ₹), with an average decrease of 1.2% per quarter
Infosys News
Dr Reddy's and Lupin Recall Products in US Due to Manufacturing Errors
Princeton-based Dr Reddys Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted.22 Apr, 2025 05:45 PMDr Reddy's and Lupin Recall Products in US Due to Errors
Dr Reddys Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. A US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddys Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to defective products that can cause serious health problems.22 Apr, 2025 05:32 PMDr Reddy's and Lupin Recall Drugs in US Due to Errors
Dr Reddys and Lupin Recall Drugs in US Due to Errors. A US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddys Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up. The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. A Class I recall pertains to defective products that can cause serious health problems.22 Apr, 2025 05:27 PMInfosys Financials
Infosys Index Inclusions
Infosys Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 13.05% | 0.00 | |
| Foreign Institutions | 30.12% | 0.07 | |
| Mutual Funds | 18.14% | 1.78 | |
| Retail Investors | 12.32% | ||
| Others | 26.37% |
Infosys Key Indicators
Infosys Valuation
Infosys in the last 5 years
Lowest (13.79x)
March 23, 2020
Today (22.50x)
April 21, 2025
Industry (30.38x)
April 21, 2025
Highest (38.37x)
December 30, 2021
Infosys Earnings and Dividends
Infosys Ltd Earnings Results
Infosys Ltd’s net profit fell -11.75% since last year same period to ₹7,033Cr in the Q4 2024-2025. On a quarterly growth basis, Infosys Ltd has generated 3.34% jump in its net profits since last 3-months.
Read More about Earnings ResultsInfosys Ltd Dividends October,2024
In the quarter ending September 2024, Infosys Ltd has declared dividend of ₹21 - translating a dividend yield of 3.38%.
Read More about Dividends
Infosys Technicals Summary
Bearish
Neutral
Bullish
Infosys Ltd is currently in a Bearish trading position according to technical analysis indicators.
Infosys Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹6,02,638.53 Cr | 25.21% | 0.53 | ₹26,248 Cr | ₹1,53,670 Cr | |
| BUY | ₹1,27,325.75 Cr | 40.59% | 0.54 | ₹4,584 Cr | ₹35,517 Cr | |
| HOLD | ₹2,49,712.00 Cr | 33.42% | 0.57 | ₹11,112 Cr | ₹89,760 Cr | |
| HOLD | ₹4,02,165.17 Cr | 44.1% | 0.53 | ₹15,710 Cr | ₹1,09,913 Cr | |
| BUY | ₹12,01,783.95 Cr | 17.54% | 0.55 | ₹48,797 Cr | ₹2,55,324 Cr |
About Infosys
Infosys operates in over 50 countries, including the United States, Canada, the United Kingdom, Australia, and various nations in Europe and Asia, providing services to clients across industries such as finance, healthcare, manufacturing, and retail. The company does not have specific sub-brands but offers various products and platforms, such as Finacle, a banking solution, and Infosys Nia, an artificial intelligence platform. Notably, Infosys is recognized for its innovative approach to technology and has been a pioneer in the global IT services industry. Additionally, Infosys has made several strategic acquisitions over the years, including companies like WongDoody and Simplus, to strengthen its capabilities in digital, cloud, and customer experience.
Revenue: ₹40,925.00Cr as on March 2025 (Q1 25)
Net Profit: ₹7,038.00Cr as on March 2025 (Q1 25)
Listing date: 03 Nov, 1994
Chairperson Name: Nandan M Nilekani
| Organisation | Infosys |
| Headquarters | |
| Industry | IT - Software |
| E-voting on shares | Click here to vote |
FAQs on Infosys Ltd
What is Infosys Ltd price today?
Infosys Ltd share price today stands at ₹1422.8, Open: ₹1440, Previous Close: ₹1451, High: ₹1440, Low: ₹1419.3, 52 Week High: ₹2006.45, 52 Week Low: ₹1307.
How to Buy Infosys Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Infosys Ltd shares
What are today's traded volumes of Infosys Ltd?
Today's traded volume of Infosys Ltd(INFY) is 94.00L.
What is today's market capitalisation of Infosys Ltd?
Today's market capitalisation of Infosys Ltd(INFY) is ₹602638.53Cr.
What is the 52 Week High and Low Range of Infosys Ltd?
How much percentage Infosys Ltd is down from its 52 Week High?
Infosys Ltd (INFY) share price is ₹1422.8. It is down -29.09% from its 52 Week High price of ₹2006.45
How much percentage Infosys Ltd is up from its 52 Week low?
Infosys Ltd (INFY) share price is ₹1422.8. It is up 8.86% from its 52 Week Low price of ₹1307